Why Resilience Matters for Plasma-Derived Medicinal Products – PPTA Europe
PPTA Europe shared a post on LinkedIn:
”At today’s Friends of Europe panel on reimagining Europe’s health systems, the discussion focused on why health must be treated as strategic infrastructure for Europe’s economy, resilience and preparedness.
For plasma-derived medicinal products, resilience depends on recognising how these therapies are made – and getting the details right as the EU implements the general pharmaceutical legislation, the Critical Medicines Act and the Biotech Act.
PDMPs rely on healthy plasma donors, specialised infrastructure, complex supply chains, and manufacturing timelines that cannot be shortened overnight.
- One-size-fits-all solutions will not work for all critical medicines
- Health must be integrated into debates on preparedness, strategic autonomy and long-term investment
- Prevention, equity and practical implementation must guide how Europe plans for the future
Europe cannot reduce vulnerabilities in a single decision.
But realistic policy choices can help strengthen supply, support innovation and keep treatment available for the patients who depend on it.
Stay updated with Hemostasis Today.
-
Sep 13, 2026, 05:36Speaking Up When Women’s Health Concerns Are Dismissed – Haemophilia Foundation Australia
-
Sep 13, 2026, 05:16W. Alberto Sifuentes Giraldo: Dual Targeted Therapy Shows Promise in Refractory Systemic Autoinflammatory Diseases
-
Sep 13, 2026, 04:42Christopher Robinson: Early Pregnancy Oxylipins May Signal Risk of Fetal Growth Restriction
-
Sep 13, 2026, 04:22Gabriela Hobbs: 2026 Society of Hematologic Oncology Meeting
-
Sep 13, 2026, 03:40Mizinga Moonze: When Blood Speaks – The Missing Link in Healthcare Sustainability
-
Sep 12, 2026, 17:55Dries De Wolf: Honored to Have Wolfgang Miesbach Comment on Our Latest Research
-
Sep 12, 2026, 17:53Usman Waheed: Introducing the Discovery of the 49th ISBT Blood Group System
-
Sep 12, 2026, 17:51Maria Sabater Lleal: Happy to Share Our Latest Work Exploring the Genetic Determinants of PE in VTE
-
Sep 12, 2026, 17:51Jeff Sternlicht: Why LDL-C and ApoB Remain King of the Hill?